Myeloma Study with Promising First Results of Iberdomide Maintenance in Phase 2 EMN26 Study Post Stem-Cell Transplantation
Dr. Niels W.C.J. van de Donk discusses the safety and clinical activity of 3 different doses of iberdomide as a novel maintenance treatment post-transplant in newly diagnosed multiple myeloma patients.
Abstract title:
Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study Presented at ASH 2023.
What is the purpose of this trial?
This trial aims to study a new oral medication called iberdomide in the treatment of multiple myeloma. Iberdomide has shown promise in previous studies for its ability to directly fight tumors and stimulate the immune system, offering potential advantages over existing medications like lenalidomide or pomalidomide.
In an earlier study involving patients with multiple myeloma resistant to multiple treatments, iberdomide combined with dexamethasone demonstrated both safety and meaningful effectiveness. This current trial focuses on evaluating the safety and effectiveness of three different doses of iberdomide as a maintenance treatment after a stem cell transplant in individuals newly diagnosed with multiple myeloma.
The goal is to understand how well iberdomide works in this specific setting, particularly after at least six treatment cycles or earlier discontinuation. The findings from this study could contribute valuable insights into improving treatment options for individuals with newly diagnosed multiple myeloma, potentially offering a novel and effective maintenance therapy post-transplant.
In this video:
Niels W.C.J. van de Donk, MD, PhD, (Amsterdam University Medical Center — Amsterdam, the Netherlands) discusses the safety and clinical activity of 3 different doses of iberdomide as a novel maintenance treatment post-transplant in newly diagnosed multiple myeloma patients. She reports the results of the first interim analysis for patients who have been treated with at least 6 treatment cycles, or discontinued treatment earlier.
Conclusion:
In transplant-eligible, newly diagnosed multiple myeloma patients, the addition of Sarclisa (isatuximab) to Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone (KRd) induction and consolidation significantly increased minimal residual disease (MRD) negativity rates in every treatment phase as compared to KRd, with no new safety concerns. This benefit was retained in high-risk myeloma patients.
Trial information: Abstract #208
Doctor bio:
Niels W.C.J. van de Donk, MD, PhD, is a Professor in Hematology at the Amsterdam University Medical Center, having entered this role in February 2020. He completed his specialization in hematology at the University Medical Center Utrecht and further honed his expertise during a fellowship at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute in Boston.
Dr. van de Donk's primary focus is on advancing the treatment options for patients with multiple myeloma. As the principal investigator of various investigator-initiated studies, he actively explores novel therapeutic targets, particularly in the realm of immune therapy. His research spans preclinical studies evaluating new agents, early-phase clinical trials, and advanced investigations, encompassing antibodies, bispecific antibodies, antibody-drug conjugates, CAR T cells, and next-generation immunomodulatory drugs.
Beyond his research endeavors, Dr. van de Donk shares his wealth of knowledge as an author or co-author of several books and numerous papers published in peer-reviewed journals. He plays a key role in collaborative efforts, serving as the secretary of the HOVON multiple myeloma working party and the scientific secretary of the European Myeloma Network. Since 2018, he has been an integral part of the European Hematology Association (EHA) Scientific Program Committee.
